4534.T
BuyUnloved QualityAI neutralMochida Pharmaceutical Co., Ltd. · Healthcare · Japan · $733M
JPY 3,130 +1.3% · close 6 Oct · scored 7 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Mochida Pharmaceutical is a Japanese drugmaker with cardiovascular, gastrointestinal and dermatology products and a skincare line. It has a net cash balance sheet and is buying back shares (0.66% in 90 days), but Japan's regular drug price cuts and patent expiries limit growth.
ABOUT MOCHIDA PHARMACEUTICAL CO., LTD.
Read
Mochida Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and sale of prescription drugs, specializing in areas such as obstetrics, gynecology, cardiovascular disease, and dermatology. The company emphasizes innovative drug discovery and development, particularly targeting unmet medical needs in its chosen therapeutic fields. Mochida's focused approach enables it to secure a strong position in niche pharmaceutical markets within Japan.
FINANCIAL SUMMARY (JPY)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | 110.2B | 103.3B | 102.9B | 105.2B | 117.0B | 1.5% | 122.4B |
| EPS (JPY) | 277.39 | 178.93 | 126.80 | 160.36 | 222.96 | -5.3% | 223.79 |
| Shares | 40.2M | 36.5M | 35.5M | 35.5M | 35.4M | -11.7% | 35.2M |
| Debt | 34.5B | — | — | 0 | 10.0B | -26.6% | 10.0B |
| Equity | 128.6B | 126.8B | 128.0B | 130.7B | 140.3B | 2.2% | — |
| Op CF | 7.5B | 7.3B | -7.5B | 9.4B | -7.3B | 7.8% | -7.2B |
| Inv CF | -2.0B | -2.9B | 74.0M | 17.4B | -16.8B | — | — |
| Fin CF | -6.0B | -6.9B | -6.4B | -2.9B | 7.0B | — | — |
Calmer than 83% of stocks we rank over the past year (24% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 4534.T are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 4534.T | Mochida Pharmaceutical Co., Ltd.(you) | $733M | 80 | Buy |
| 4521.T | Kaken Pharmaceutical Co., Ltd. | $952M | 80 | Strong Buy |
| 4553.T | Towa Pharmaceutical Co., Ltd. | $1.2B | 77 | Buy |
| 4559.T | Zeria Pharmaceutical Co., Ltd. | $564M | 90 | Strong Buy |
| 4540.T | Tsumura & Co. | $1.8B | 80 | Strong Buy |
| 4554.T | Fuji Pharma Co., Ltd. | $299M | 85 | Strong Buy |
| 4516.T | Nippon Shinyaku Co., Ltd. | $1.5B | 91 | Strong Buy |
| 4569.T | KYORIN Pharmaceutical Co., Ltd. | $411M | 65 | Hold |
| 4886.T | ASKA Pharmaceutical Holdings Co.,Ltd. | $386M | 64 | Hold |
| 4577.T | Daito Pharmaceutical Co.,Ltd. | $240M | 73 | Buy |
Peer medians: ROE 8.3% · P/E 15.7x · Gross margin 47.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.